<DOC>
	<DOCNO>NCT02448732</DOCNO>
	<brief_summary>The purpose study investigate role intravitreal injection anti-vascular endothelial growth factor ( VEGF ) therapy prevention control ophthalmological neovascular disease , order find new strategy treatment ophthalmological neovascular disease</brief_summary>
	<brief_title>Exploratory Clinical Trials ACM-1 Treatment Ophthalmological Neovascular Diseases</brief_title>
	<detailed_description>Ophthalmological neovascular disease one major cause blindness ocular disease . Up , major treatment strategy include : anti-VEGF therapy , laser therapy surgery . Clinical treatment reveal intravitreal injection anti-VEGF effectively restrain neovascularization . Nevertheless , require repeated injection , may result various complication , may ineffective patient . Therefore , necessary find targets cause retinal neovascularization , order find effective treatment patient fail respond anti-VEGF therapy . Previous research show herb monomer ( ACM-1 ) effective inhibiting leakage retinal vessel neovascularization . So study , patient ophthalmological neovascular disease treat intravitreal injection ACM-1 , order investigate role intravitreal injection ACM-1 therapy prevention control ophthalmological neovascular disease .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>1. age range 18 75 year old 2. without light perception ( NLP ) 3 . A large number iris retinal neovascularizations , neovascular glaucoma need cyclophotocoagulation enucleation eyeball 4 . The best corrected visual acuity contralateral eye well 0.05 5 . Followup six month 6 . Volunteer project sign inform consent 1 . The best corrected visual acuity contralateral eye low 0.05 2 . Severe systemic disease surgical contraindication 3. history antiangiogenic therapy within one month 4 . Ocular neovascularization cause reason , endophthalmitis 5. history join drug clinical trial within one month ( except vitamin mineral ) 6. premenopausal woman use birth control 7. people currently treat systemic infection 8 . Allergic fluorescein 9. hypertension ( SBP higher 140mmHg ) 10. hepatic renal dysfunction 11 . History drug abuse alcoholism 12. situation impede clinical trial , depressive disorder 13. compliance poor finish clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ACM-1</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>neovascularization</keyword>
</DOC>